Table 1. Demographic and baseline values.
| Variable | All | Tacrolimus | Cyclosporine |
| Number of patients | 52 | 39 | 13 |
| Age, median (interquartile range) | 62 (58,65) | 62 (58,65) | 60 (55,63) |
| Gender | |||
| Male (%) | 42 (80.77) | 31 (79.49) | 11 (84.62) |
| Ethnicity | |||
| Hispanic (%) | 18 (34.62) | 12 (30.77) | 6 (46.15) |
| Non-Hispanic White (%) | 16 (30.77) | 11 (28.21) | 5 (38.46) |
| Other (%) | 18 (34.62) | 16 (41.03) | 2 (15.38) |
| Body Mass Index (kg/m2), median (interquartile range) | 26.8 (23.69, 29.78) | 25.73 (23.23, 29.55) | 28.59 (25.58, 30.94) |
| Months since liver transplant, median (interquartile range) | 32.9 (13.78, 74.42) | 29.18 (13.09, 60.82) | 59.24 (39.63, 179.60) |
| Mycophenolate | |||
| Before Treatment | 36 (69.23) | 29 (74.36) | 7 (53.85) |
| After Treatment | 35 (67.31) | 26 (66.67) | 9 (69.23) |
| Sirolimus | |||
| Before Treatment | 1 (1.92) | 0 (0) | 1 (7.69) |
| After Treatment | 2 (3.85) | 1 (2.56) | 1 (7.69) |
| Hepatitis C Treatment Experienced (%) | 23 (44.2) | 14 (35.9) | 9 (69.2) |
| Antiviral Therapy | |||
| Sofosbuir/Ribavirin (%) | 31 (59.6) | 23 (59) | 8 (61.5) |
| Sofosbuir/Simeprevir (%) | 21 (40.4) | 16 (41) | 5 (38.5) |
| Non-hepatic comorbidities | |||
| Cardiac disease (%) | 5 (9.6) | 5 (12.8) | 0 (0) |
| Hemodialysis (%) | 3 (5.77) | 2 (5.13) | 1 (7.69) |
| Cerebral vascular stroke (%) | 1 (1.92) | 1 (2.56) | 0 (0) |
| Non-liver malignancy (%) | 5 (9.6) | 4 (10.3) | 1 (7.69) |
| Diabetes (%) | 17 (32.69) | 13 (33.33) | 4 (30.77) |
| Lymphoma (Non-PTLD) (%) | 1 (1.92) | 0 (0) | 1 (7.7) |